Joshua Uhr is an Ophthalmology physician. OpenAlex indexes 30 publications with 503 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4060 Butler Pike Ste 200
Plymouth Meeting, PA 194621560
Telephone
800-331-6634Provider last certified this registry record 11 Jun 2024.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Bausch & Lomb Americas Inc.Program year20257 payments
- Apellis Pharmaceuticals, Inc.Program year20252 payments
- Regeneron Pharmaceuticals, Inc.Program year20244 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
87.2%Antineovascularisation agents86%Faricimab-svoa100%Part B, office-administered≥72 patientsCorticosteroid0.6%Prednisolone Acetate100%Part D≥49 patients+ 3 more classes in this area
Cancer & immunology
12.3%Vascular Endothelial Growth Factor Inhibitor6.5%Aflibercept96%Bevacizumab4%Part B, office-administered≥136 patientsComplement Inhibitor5.8%Pegcetacoplan100%Part B, office-administered≥23 patientsMusculoskeletal
0.4%Cyclooxygenase Inhibitor0.4%Ketorolac Tromethamine100%Part D≥25 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Indications and Outcomes of Select Vitreoretinal Surgery in Patients With Marfan Syndrome
Journal of VitreoRetinal Diseases
2025 - Economic Evaluation of Artificial Intelligence Systems Versus Manual Screening for Diabetic Retinopathy in the United States
Ophthalmic surgery, lasers & imaging retina
2023 - Cytomegalovirus Retinitis Associated With Intravitreal Dexamethasone Implant Injection
Journal of VitreoRetinal Diseases
2023 - <i>Nocardia</i> Scleritis Progressing to Endophthalmitis in the Setting of Scleral Buckle Extrusion
Ophthalmic surgery, lasers & imaging retina
2023 - Limitations of direct-to-consumer genetic testing for age-related macular degeneration
European Journal of Ophthalmology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”